Pediatric Hyperparathyroidism Differential Diagnoses

  • Author: Gordon L Klein, MD, MPH; Chief Editor: Stephen Kemp, MD, PhD   more...
 
Updated: Mar 23, 2012
 
 

Differential Diagnoses

Proceed to Workup
 
 
Contributor Information and Disclosures
Author

Gordon L Klein, MD, MPH  Clinical Professor of Orthopedic Surgery and Rehabilitation, University of Texas Medical Branch School of Medicine

Gordon L Klein, MD, MPH is a member of the following medical societies: American Academy of Pediatrics, American Gastroenterological Association, American Pediatric Society, American Society for Bone and Mineral Research, American Society for Nutritional Sciences, North American Society for Pediatric Gastroenterology and Nutrition, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Specialty Editor Board

Phyllis W Speiser, MD  Chief, Division of Pediatric Endocrinology, Steven and Alexandra Cohen Children's Medical Center of New York; Professor of Pediatrics, Hofstra-North Shore LIJ School of Medicine at Hofstra University

Phyllis W Speiser, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, Endocrine Society, Pediatric Endocrine Society, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London)  Professor and Chair, First Department of Pediatrics, Athens University Medical School, Aghia Sophia Children's Hospital, Greece; UNESCO Chair on Adolescent Health Care, University of Athens, Greece

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London) is a member of the following medical societies: American Academy of Pediatrics, American College of Endocrinology, American College of Physicians, American Pediatric Society, American Society for Clinical Investigation, Association of American Physicians, Endocrine Society, Pediatric Endocrine Society, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Merrily P M Poth, MD  Professor, Department of Pediatrics and Neuroscience, Uniformed Services University of the Health Sciences

Merrily P M Poth, MD is a member of the following medical societies: American Academy of Pediatrics, Endocrine Society, and Pediatric Endocrine Society

Disclosure: Nothing to disclose.

Chief Editor

Stephen Kemp, MD, PhD  Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas for Medical Sciences College of Medicine, Arkansas Children's Hospital

Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, and Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

References

  1. Kifor O, Moore FD Jr, Wang P. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab. Apr 1996;81(4):1598-606. [Medline].

  2. Silverberg SJ, Bilezikian JP. Primary Hyperparathyroidism. In: Rosen CJ. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Seventh. Washington DC: American Society for Bone and Mineral Research; 2008:302-6.

  3. McMullen T, Bodie G, Gill A, et al. Hyperparathyroidism after irradiation for childhood malignancy. Int J Radiat Oncol Biol Phys. Mar 15 2009;73(4):1164-8. [Medline].

  4. Al-Khalaf FA, Ismail A, Soliman AT, Cole DE, Ben-Omran T. Neonatal severe hyperparathyroidism: further clinical and molecular delineation. Eur J Pediatr. May 2011;170(5):625-31. [Medline].

  5. Richert L, Trombetti A, Herrmann FR, et al. Age and gender distribution of primary hyperparathyroidism and incidence of surgical treatment in a European country with a particularly high life expectancy. Swiss Med Wkly. July 2009;11:400-4. [Medline].

  6. Libansky P, Astl J, Adamek S, et al. Surgical treatment of primary hyperparathyroidism in children: Report of 10 cases. Int J Pediatr Otorhinolaryngol. Aug 2008;72(8):1177-82. [Medline].

  7. Khosla S, Melton III LJ, Wermers RA. Primary hyperparathyroidism and the risk of fractures: A population-based study. J Bone Miner Res. 1999;14:1700-1707. [Medline].

  8. Sneider MS, Solorzano CC, Montano RE, Anello C, Irvin GL 3rd, Lew JI. Sporadic primary hyperparathyroidism in young individuals: different disease and treatment?. J Surg Res. 2009;155:100-3. [Medline].

  9. Silverberg SJ, Shane E, Jacobs TP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341:1249-1255. [Medline].

  10. Benaderet AD, Burton AM, Clifton-Bligh R, Ashraf AP. Primary hyperparathyroidism with low intact PTH levels in a 14-year-old girl. J Clin Endocrinol Metab. Aug 2011;96(8):2325-9. [Medline]. [Full Text].

  11. Muscheites J, Wigger M, Drueckler E, Fischer DC, Kundt G, Haffner D. Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr Nephrol. May 27 2008;[Medline].

  12. Wilhelm-Bals A, Parvex P, Magdelaine C, Girardin E. Successful use of bisphosphonate and calcimimetic in neonatal severe primary hyperparathyroidism. Pediatrics. Mar 2012;129(3):e812-6. [Medline].

  13. Sanchez CP. Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment. Paediatr Drugs. 2003;5(11):763-76. [Medline].

  14. Seeherunvong W, Nwobi O, Abitbol CL, Chandar J, Strauss J, Zilleruelo G. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr Nephrol. Oct 2006;21(10):1434-9. [Medline].

  15. Arnold A. Familiar hyperparathyroid syndromes. In: Favus MJ. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Sixth. Washington DC: American Society for Bone and Mineral Research; 2006:185-188.

  16. Aubin JE, Lian JB, Stein GS. Bone Formation: Maturation and Functional Activities of Osteoblast Lineage Cells. In: Favus MJ. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Sixth. Washington DC: American Society for Bone and Mineral Research; 2006:20-29.

  17. Bilezekian JP, Silverberg SJ. Primary Hyperparathyroidism. In: Favus MJ. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Sixth. Washington DC: American Society for Bone and Mineral Research; 2006:181-185.

  18. Hebert SC. Therapeutic use of calcimimetics. Annu Rev Med. 2006;57:349-64. [Medline].

  19. Langman CB. Hypercalcemic Syndromes in Infants and Children. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Sixth. Washington DC: American Society for Bone and Mineral Research; 2006:209-212.

  20. Martin KJ, Al-Aly Z, Gonzalez EAl. Renal Osteodystrophy. In: Favus MJ. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Sixth. Washington DC: American Society for Bone and Mineral Research; 2006:359-366.

  21. Marx SJ. Familial Hypocalciuric Hypercalcemia. In: Familial hypocalciuric hypercalcemia. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Sixth. Washington DC: American Society for Bone and Mineral Research; 2006:188-190.

  22. Morony S, Capparelli C, Lee R. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1 beta, TNF-alpha, PTH, PTHrP, and 1,25 (OH)2D3. J Bone Miner Res. 1999;14:1478-1485. [Medline].

  23. National Kidney Foundation. Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kid Dis. 2003;42 suppl 3:S1-202.

  24. Ross FP. Osteoclast Biology and Bone Resorption. In: Favus MJ. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Sixth. Washington DC: American Society for Bone and Mineral Research; 2006:30-35.

  25. United States Pharmacopeia. Vitamin D and Analogs Systemic. USP Dispensing Information: Advice to the Health Care Professional. 2004;1:2849-57.

  26. Vestergaard P, Nielsen LR, Mosekilde L. [Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism]. Ugeskr Laeger. Jan 3 2006;168(1):29-32. [Medline].

  27. Wada M, Nagano N, Nemeth EF. The calcium receptor and calcimimetics. Curr Opin Nephrol Hypertens. 1999;8:429-433. [Medline].

 
Previous
Next
 
Normal parathyroid glands as seen during a thyroidectomy. The large arrow points to the superior parathyroid. The thinner arrow points to the inferior parathyroid. The forceps points toward the recurrent laryngeal nerve. The patient's head is toward the right.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.